TargetMol

LY-2624803

Product Code:
 
TAR-T24421
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T24421-1mg1mg£185.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24421-5mg5mg£360.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24421-10mg10mg£496.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24421-25mg25mg£760.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24421-50mg50mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24421-100mg100mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24421-500mg500mg£2,633.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
LY2624803 is a 5-HT2A and histamine, H1 receptor antagonist. LY2624803 has specific histamine and serotonin receptor antagonism and does not produce other unwanted side effects.
CAS:
879409-35-5
Formula:
C22H25N3O3
Molecular Weight:
379.46
Pathway:
Neuroscience|GPCR/G Protein|Immunology/Inflammation
Purity:
0.98
SMILES:
O=C(O)C(C)(C)CN1CCN(C2=NC3=CC=CC=C3OC4=CC=CC=C24)CC1
Target:
5-HT Receptor|Histamine Receptor

References

1. Zisapel N. Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11. doi: 10.1517/13543784.2015.987340. Epub 2014 Nov 25. Review. PubMed PMID: 25423562.